H1 Blog

MAY 11, 2023

Omnichannel engagement for physician marketing is a powerful tool for biotechnology and pharma companies looking to increase reach and drive engagement among HCPs. Additionally, social media analytics can help marketers identify influential HCPs who can become valuable advocates for their product or treatment.

Pharma Companies 52

Pharma Companies Marketing Treatment Pharmaceuticals 52

H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

Alta Sciences

MARCH 27, 2024

Eryn has a wealth of expertise in diverse therapeutic areas and, after her experiences with battling cancer, a commitment to advancing the pharmaceutical industry by merging conventional and alternative treatments into one model. Get to know Eryn with this Q&A: What motivated you to pursue a doctorate degree?

Drug Development 52

Drug Development Medical Schools Pharma Companies Drugs 52

The Pharma Data

JANUARY 17, 2021

Billions of dollars are poured into research each year, yet the push for effective treatment and hope for a cure is dashed time and again. Connecticut-based Biohaven Pharmaceuticals was looking pretty hopeful with its third-generation prodrug to modulate glutamate, the most abundant excitatory neurotransmitter in the human body.

Pharma Companies 52

Pharma Companies Disease Treatment Trials 52

Eye on FDA

JANUARY 9, 2022

As noted in the past, there are two primary means for understanding the agency’s latest thinking with respect to promotional communications from pharmaceutical companies – the content and pattern of enforcement and the issuance of guidance documents to shed light on the parameters that exist. Why This is a Fail.

FDA 64

FDA Pharma Companies Pharmaceutical Companies Treatment 64

Drug Target Review

OCTOBER 1, 2024

Following clinical practice, I transitioned to the world of pharmaceutical companies which also had its challenges as I had to learn everything from scratch and use my experience and knowledge differently. Moreover, increasing treatment complexity will require more sophisticated scientific exchange.

Doctors 97

Doctors Therapies Science Pharma Companies 97

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 124

Therapies Virus DNA Clinical Trials 124

Drug Target Review

JULY 11, 2024

Therefore, to create targeted treatments there is the need to develop novel technologies to identify targets on the surface of cancer cells. Scientists and, increasingly, biotechs and pharma companies hope to create a more detailed map of the surfaceome, the entire cancer cell surface and its membrane-bound proteins.

Therapies 56

Therapies RNA Pharma Companies Disease 56

The Pharma Data

NOVEMBER 20, 2020

Pharma leaders fear extreme vulnerability in end-to-end supply chain as pandemic continues, according to global survey. Explore how pharma companies and industry leaders can reset for growth in the lab beyond coronavirus in Pharma IQ ’s fourth annual edition of Smart Lab Digital. Save your early bird seat now.

Pharma Companies 52

Pharma Companies Vaccine Drugs Pharmacy 52

The Pharma Data

SEPTEMBER 14, 2020

The availability of new analytics tools and the expansion of data sources has led many pharma companies to adopt a data-driven approach to decision-making during the early stages of the clinical trial planning process. Accelerating your clinical trial supply through digitalization.

Clinical Supply 52

Clinical Supply Clinical Trials Pharma Companies Trials 52

The Open Targets Blog

OCTOBER 24, 2023

OMass Therapeutics is using a new technology platform to develop treatments for rare immunological and genetic diseases with high unmet patient needs. Although pharma companies can be competitive, this kind of tool will not generate any IP, and it saved us so much work that we knew it could be of real benefit to the community.

Bioinformatics 63

Bioinformatics Packaging Pharmaceutical Companies Pharma Companies 63

The Pharma Data

DECEMBER 21, 2020

Medical Director and Head of the Immunological Tumor Group at University Medicine Halle, Germany, who is a renowned oncology clinician and researcher specializing in the analysis of immuno-oncology treatments and their interaction with tumor tissues. Mascha Binder, M.D.,

Vaccine 52

Vaccine Trials Clinical Trials Clinical Development 52

The Pharma Data

DECEMBER 23, 2020

Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. All study subjects will receive the same Ampligen treatments. I believe the data to date suggests that early treatment will lead to better levels of efficacy.”. development pipeline for ME/CFS. See: PLOS ONE ). AIM CEO Thomas K.

Clinical Trials 52

Clinical Trials Trials Virus Therapies 52

The Pharma Data

DECEMBER 17, 2020

Hartfield previously served as CEO of Vitae Pharmaceuticals prior to its acquisition by Allergan. X4 Pharmaceuticals – Diego Cadavid was named chief medical officer of Boston-based X4 Pharmaceuticals. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

Small Molecule 52

Small Molecule Clinical Development Engineering Pharmaceuticals 52

Predictive Oncology

FEBRUARY 7, 2023

With its technology, the company wants to change the way that biopharma companies plan clinical trials and develop oncology drugs. This is all about getting the right drugs to the right patients at the right time as soon as possible to personalize the treatment of their therapies, primarily in oncology,” said Vennare.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials Pharmaceuticals 52

H1 Blog

MARCH 27, 2023

As the primary interface between healthcare providers (HCPs) and pharmaceutical companies, medical science liaisons (MSLs) have a unique opportunity to engage with HCPs in clinical discussions and bridge care gaps by providing crucial insights into evidence-based medicine.

Science 52

Science Pharma Companies Pharmaceutical Companies Treatment 52

Vial

FEBRUARY 19, 2024

Explore the groundbreaking VersAptx bioconjugation platform, designed to elevate cancer therapies and uncover the delicate balance between clinical excellence and commercial viability in the dynamic landscape of pharmaceuticals. I veered into oncology and oncology research earlier in my career. Ahmed Hamby: Thank you.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

The Anticancer Fund

JUNE 7, 2022

Treatment with DFMO aka eflornithine, already a high-profile repurposing candidate in neuroblastoma, decreased intracellular pH in TAMCs and was associated with improved survival, more so when combined with immunotherapy or radiotherapy. Median PFS (9.25

Drugs 40

Drugs Clinical Trials Trials Treatment 40

Advarra

JULY 19, 2022

Q: If an emergency use authorization (EUA) is granted, once there is an approved treatment, does that mean that the EUA is no longer valid? The sponsor is the pharmaceutical company conducting the trial. A: Working in a pharmaceutical company is the best way to learn this. A: Yes, the EUA is just temporary.

Packaging 52

Packaging FDA Trials Regulations 52

Altus Drug Development

JUNE 28, 2022

Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Doctors Treatment 52

The Pharma Data

MAY 13, 2021

In this special report, I’m going to show you why researchers at Harvard University and the Massachusetts General Hospital in Boston are now praising a strange new pain treatment originally discovered on the International Space Station. ” Here’s The Dirty Little Secret Of The Pharmaceutical Industry. Dr TK Huynh Pain Therapist.

Pharmacy 52

Pharmacy Doctors Production Therapies 52

The Pharma Data

OCTOBER 14, 2020

AOP Orphan – AOP Orphan Pharmaceuticals took over the Viennese pharmaceutical company Amomed and the Luxembourgish health-tech company SciPharm. Food and Drug Administration granted Breakthrough Therapy designation to France-based Inventiva’s experimental NASH treatment lanifibranor. adults age 65 and older.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Therapies 52

The Pharma Data

JANUARY 24, 2021

.–( BUSINESS WIRE )– Faze Medicines , a biotechnology company pioneering therapeutics based on the groundbreaking new science of biomolecular condensates, today announced that it has appointed Philip Vickers, Ph.D., Dr. Vickers has over 30 years of experience as a researcher and leader in the pharmaceutical industry.

Pharma Companies 52

Pharma Companies Small Molecule Science Disease 52

H1 Blog

DECEMBER 11, 2024

Drug Pricing, Global Diversity Strategies, & Emerging AI Applications Each year, we compile our predictions to provide life sciences, pharmaceutical, and healthcare organizations with a comprehensive look at emerging industry trends and dynamics to help them prepare for the year ahead.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Treatment 52

The Pharma Data

NOVEMBER 11, 2020

TOKYO & AUSTIN, Texas–( BUSINESS WIRE )– Taiho Pharmaceutical Co., There currently are no approved drug treatment options for this condition. We are honored to partner with Taiho, a Japanese pharmaceutical company with a commitment to the respiratory field, for the development and commercialization of LTI-01 in Japan.

Licensing 40

Licensing Licensing Treatment Pharma Companies 40

Drug Target Review

MAY 23, 2023

Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.

Drugs 75

Drugs Small Molecule Production Disease 75

The Pharma Data

DECEMBER 30, 2020

It also calls for ending the tax deductions that pharmaceutical companies can take for the amount of money it spends on advertising its medications. Four big companies are cited as possible tasty takeover targets for 2021. They are: • BioMarin Pharmaceutical. The company has a market cap of $15.4

Vaccine 52

Vaccine FDA Trials Therapies 52

The Pharma Data

MAY 16, 2021

Including the pharmaceutical corporation’s wallet-sucking chemical solutions. Especially considering the cost of “mainstream” treatment remedies out there. Or you could try one of the latest treatments like the P-Shot or Shockwave therapy…. We’ll start with all-natural food #1 which contains powerful compounds that….

Production 52

Production Science Doctors Research 52

Drug Target Review

MARCH 13, 2025

Techbio companies have initiated this approach. Now even non-AI native big pharma companies take a similar view on using clinical genomics with integrated multimodality. About the authors Remco Jan Geukes Foppen , PhD, is an AI and life sciences expert specialising in the pharmaceutical sector.

Drug Development 59

Drug Development Science Clinical Trials FDA 59

Drug & Device Law

SEPTEMBER 1, 2023

We observed oral argument the other day in a case that could have a significant impact on potential liability under California tort law for pharma companies and all other innovators. In Gilead v. Superior Court , No. A165558 (Cal. First Dist.), Superior Court , which plaintiffs have to find a way around.

Production 64

Production Marketing Drugs Pharma Companies 64

Drug & Device Law

APRIL 7, 2023

The case is Vanda Pharmaceuticals, Inc. 27, 2023), and the plaintiff was a pharmaceutical company that wanted to know what the FDA really thought of its drug. The company lodged a request under the Freedom of Information Act (“FOIA”), which the FDA refused. 22-cv-938, 2023 U.S. LEXIS 51853 (D.D.C. Here is what happened.

FDA 64

FDA Government Pharma Companies Regulations 64